Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 329

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1A
Chunk 329
---
 Texas and is noted for her groundbreaking transdisciplinary and cross-sector work in systems design.
As a voting member of the Cherokee Nation, she has lifetime involvement in equity programs and has testified before Congress. In addition
to serving on several start-up boards, Dr. Jacobs founded the National Coalition of Ethnic Minority Nurse Associations funded by the
NIH National Institute of General Medical Sciences. Prior to her current role at Georgetown, she served as dean at the Georgetown School
of Nursing and Health Studies, vice president for Honda of America Manufacturing, associate director of applied research at UAB Civitan
International Research Center and acting dean of graduate studies and research at California State University. She has been a fellow
and visiting professor at the University of Oxford and an academic guest scholar and lecturer at several acclaimed universities worldwide.
Her wealth of experience in research, administration and serving on boards coupled with her unique background and perspectives makes
her ideally suited to serving as a member of our Board of Directors.

Scientific
Advisory Committee

Theodore
L. Phillips, M.D. has served as the Chair of our Scientific Advisory Committee since 2018. He held the position of Chief Medical
Officer and Clinical Director at Shuttle Pharmaceuticals from 2014 until 2018. Dr. Phillips’ distinguished career has included
positions of Chair of the Department of Radiation Oncology (from1978 to 1998) and Associate Director (from 1996 to 1999) of the UCSF
Cancer Center at the University of California at San Francisco. He is highly experienced in radiation oncology clinical trials of hypoxic
radiation sensitizers. Dr. Phillips served as the principal investigator of the SBIR contract for the Phase I clinical trial of Ropidoxuridine.
He previously served as Associate Director of the Northern California Oncology Group from 1983-1990, president of the American Society
of Therapeutic Radiation Oncologists from 1984 to 1985 and is an elected member of the Institute of Medicine of the National Academy
of Science. Dr. Phillips holds a BS degree from Dickinson College in Carlisle, Pennsylvania and a MD from the University of Pennsylvania.
He provides advice to the leadership team to help design and implement clinical trials of radiation therapy and radiation response modifying
drugs.

Ralph
R. Weichselbaum, M.D. has served as Scientific Advisor to Shuttle Pharmaceuticals for translational research for the discovery and
development of radiation response modifiers since 2013. Dr. Weichselbaum is